Here are 1-3 brief analogies for ANI Pharmaceuticals:

• It's like a focused **Viatris** (formerly Mylan), manufacturing and selling both generic and specialized branded prescription drugs, and also acting as a contract manufacturer for other pharmaceutical companies.

• Think of it as a highly skilled pharmaceutical manufacturer, similar to **Catalent**, but one that also develops and sells its own portfolio of generic and specialty prescription medicines.

• A specialty pharmaceutical company focusing on niche and complex drugs, akin to a more diverse **Jazz Pharmaceuticals** that also produces generics and offers contract manufacturing services.

• Controlled Substances: Prescription drugs with a high potential for abuse or dependence, produced under strict regulatory guidelines.
• Oncology Products: Pharmaceuticals specifically developed for the treatment of various types of cancer.
• Hormones and Steroids: Medicinal products containing hormonal or steroidal compounds used for therapeutic purposes.
• Injectable Pharmaceuticals: Medications specifically formulated to be administered into the body via injection.
• Oral Solid Dose Products: Pharmaceuticals manufactured in common forms such as tablets and capsules.
• Semi-solids, Liquids, and Topicals: Medications prepared as creams, gels, solutions, or suspensions for various applications.
• Potent Products: Highly effective pharmaceuticals that require specialized handling and manufacturing due to their strong pharmacological effects.
• Contract Development and Manufacturing (CDMO) Services: Providing comprehensive development and manufacturing solutions for pharmaceutical products to other companies.

ANI Pharmaceuticals (ANIP) primarily sells its products to other companies. Its major customers are large pharmaceutical wholesalers and major retail pharmacy chains.

Based on their latest public filings, the following companies represent their major customers:

• Cardinal Health, Inc. (Symbol: CAH)
• McKesson Corporation (Symbol: MCK)
• Cencora, Inc. (formerly AmerisourceBergen Corporation) (Symbol: COR)
• CVS Health Corporation (Symbol: CVS)
• Walgreens Boots Alliance, Inc. (Symbol: WBA)

Nikhil Lalwani, President and Chief Executive Officer

Nikhil Lalwani has served as ANI's President and Chief Executive Officer and a member of its Board since September 2020. Before joining ANI, Mr. Lalwani was at Cipla Ltd, a global pharmaceutical company, from May 2012 to August 2020, where he held various leadership positions including CEO of Cipla USA, CEO of InvaGen, Head of US Strategy, M&A & Integration, and Head of Cipla's Global Respiratory business. In these roles, he developed and executed multi-year strategic growth plans for key products and facilitated acquisitions as Cipla entered the specialty pharmaceutical space. Prior to Cipla, he was an Associate Partner with McKinsey & Company, advising global pharmaceutical and healthcare companies, and an engineer with Medtronic. He holds a B.S. in Electrical Engineering from Georgia Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.

Stephen P. Carey, Senior Vice President, Finance and Chief Financial Officer

Stephen P. Carey has served as ANI's Senior Vice President, Finance and Chief Financial Officer since May 2016. He brings over 30 years of experience as a financial executive, with more than 25 years in the pharmaceutical industry. Before ANI, Mr. Carey held various executive financial positions at Par Pharmaceutical Companies, Inc. from June 2007 to October 2015, including Senior Vice President, Controller and Principal Accounting Officer. During his tenure at Par, he supported the company during its $1.9 billion leveraged buyout with TPG Capital in 2012 and its subsequent sale to Endo International plc for $8 billion in 2015. Prior to Par, he held financial and accounting positions at Schering-Plough Corporation. Mr. Carey began his career at PricewaterhouseCoopers.

Chad Gassert, Senior Vice President, Corporate Development & Strategy

Chad Gassert joined ANI in November 2021 following the acquisition of Novitium Pharma, where he was a Co-Founder and CEO. At Novitium, he led the establishment of a fully integrated generic pharmaceutical company. Before Novitium, Mr. Gassert worked at Par Pharmaceuticals from 2005 to 2016, holding various positions of increasing responsibility, including Senior Vice President of Business Development.

Christopher Mutz, Senior Vice President, Head of Rare Disease

Christopher Mutz joined ANI in February 2021 and serves as the Head of its Rare Disease business. He has over 25 years of experience in the pharmaceutical industry. Prior to joining ANI, Mr. Mutz provided consulting services to pharmaceutical and biotechnology companies on pre-launch commercial strategy and life cycle management, with a focus on rare diseases. His experience includes eight years at Alexion Pharmaceuticals and ten years at Merck and Co.

Muthusamy Shanmugam, Head of Research & Development and Chief Operating Officer of New Jersey Operations

Muthusamy Shanmugam joined ANI's Board in November 2021 in connection with the company's acquisition of Novitium Pharma, where he was the President and Founder. He possesses over three decades of experience in the pharmaceutical industry. Mr. Shanmugam began his career as a formulation scientist at Kali Laboratories, Inc. and rose to become a leading formulation development scientist in the generic drug industry.

Key Business Risks for ANI Pharmaceuticals (ANIP)

1. Regulatory and Product Liability Risks: ANI Pharmaceuticals operates within a heavily regulated pharmaceutical industry, making it subject to stringent FDA requirements and guidelines. Ensuring continuous compliance with these regulations is crucial for maintaining manufacturing operations and product approvals. The company also faces inherent risks of product liability litigation, which could lead to significant financial losses and reputational damage.

2. Competitive and Pricing Pressures, and Reliance on Key Products: The pharmaceutical market in which ANIP operates is highly competitive, posing challenges from both established companies and new entrants. This intense competition can significantly impact ANI's pricing strategies, market share, and overall profitability, particularly within its generic product segments. Furthermore, ANI Pharmaceuticals is increasingly relying on its rare disease segment, especially products like Cortrophin Gel, to drive revenue growth. This concentration of revenue on a few key products exposes the company to risks associated with payer pushback on pricing and access, as well as broader market acceptance and potential new competition for these specific therapies.

3. Execution and Timing Risks of Growth Initiatives and Reimbursement Issues: ANI Pharmaceuticals' growth strategy heavily depends on the successful execution of sales expansion initiatives, particularly for Cortrophin Gel, and the effective launch of new product indications (e.g., for gout). There are identified "execution and timing risks" that could impact the realization of anticipated revenues, especially if sales expansion efforts or new indications underperform relative to increased spending on sales and research and development. Additionally, the company faces risks related to reimbursement challenges for its products, which have been noted to directly limit sales for some offerings.

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

• ANI Pharmaceuticals does not appear to pay dividends and has a negative buyback yield of -9.89% (as of the last 12 months ending March 2026), suggesting a net issuance rather than repurchases.

Share Issuance

• In November 2021, 91,000 common shares were acquired in exchange for convertible preferred shares, with an aggregate market value of approximately $7.87 million based on a proposed sale in August 2025.
• The company issued restricted shares as compensation to insiders, with acquisitions noted on May 23, 2024, August 21, 2024, and May 21, 2025.

Outbound Investments

• On September 16, 2024, ANI Pharmaceuticals acquired Alimera.
• Payments for business acquisitions totaled approximately $401.28 million in fiscal year 2024.
• In fiscal year 2021, payments for business acquisitions amounted to approximately $84.49 million.

Capital Expenditures

• Capital expenditures were approximately $16.24 million in fiscal year 2024, $8.87 million in fiscal year 2023, and $8.88 million in fiscal year 2022.
• For the last twelve months (ending September 30, 2025), capital expenditures were approximately $13.84 million.
• The company makes strategic investments in U.S. manufacturing, rare diseases, and complex generics to strengthen margins and diversify its portfolio.